Gadolinium contrast ( DrugBank: Gadolinium )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 34 | Neurofibromatosis | 1 |
34. Neurofibromatosis
Clinical trials : 137 / Drugs : 213 - (DrugBank : 76) / Drug target genes : 87 - Drug target pathways : 200
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02584413 (ClinicalTrials.gov) | April 16, 2013 | 20/10/2015 | Hypotonia and Neurofibromatosis Type 1 (NF1) Glioma | Hypotonia as a Clinical Predictor of Optic Pathway Glioma in Children With Neurofibromatosis Type 1 | Neurofibromatosis Type 1 | Device: Magnetic resonance imaging;Drug: Gadolinium contrast | Washington University School of Medicine | St. Louis Children's Hospital | Terminated | 1 Year | 7 Years | All | 29 | N/A | United States |